이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Transformed B-cell Lymphoma : Clonal Evolution, Microenvironment Remodeling and Therapeutic Targets Discovery; Prospective Program (TYPHON-P)

2026년 11월 13일 업데이트: Julien BROSÉUS, Central Hospital, Nancy, France

The progression of small B-cell lymphomas toward a more aggressive histological form, specifically, diffuse large B-cell lymphoma (DLBCL) is a serious and most often fatal event. This process gives rise to several categories of scientific challenges :

  1. Anticipating this transformation through the early detection-while the disease is still in its indolent B-cell lymphoma stage-of biological markers that predict such a shift, particularly those that define tumor sub-clones at high risk of transformation.
  2. Identifying the specific event(s) that, within an ongoing and continuous process, trigger the definitive transition from the indolent B-cell lymphoma phase to the transformed B-cell lymphoma phase.
  3. Identifying the disrupted biological functions that drive treatment resistance in the transformed B-cell lymphoma stage, with the goal of defining new therapeutic targets.

Hypothesis :

  1. The aggressive transformation of indolent B-cell lymphomas results from an imbalance in the subclonal structure, driven by the evolution of a dominant subclone that undergoes aggressive transformation. This subclonal competition-occurring either spontaneously or under therapeutic pressure-is fueled by the acquisition and/or selection of specific molecular and epigenetic alterations, as well as favorable remodeling of the tumor microenvironment. Some of these changes are detectable as early as the indolent phase, offering the prospect of early detection, while others dictate the mechanisms of therapeutic resistance following transformation.
  2. Understanding the mechanisms of therapeutic resistance in transformed DLBCL could pave the way for the development of new, effective treatments. Furthermore, these insights could potentially be applied to resistant forms of de novo DLBCL-the most common category (40%) of B-cell lymphoma.

Our primary objective is to identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of de novo DLBCL.

Secondary objective 1. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.

Secondary objective 2. To develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.

Secondary objective 3. To identify biological characteristic, at the indolent B-cell lymphoma stag, that are predictive of aggressive transformation.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

TYPHON-P is a regional, multicenter, longitudinal, and translational observational study based on the prospectivebuilding of a clinical-biological cohort and a centralized biobank, managed by the Lorraine Biological Resource Center and the Pathology Department of the Nancy University Hospital. The study will include patients with indolent B-cell lymphoma, transformed B-cell lymphoma, or de novo aggressive B-cell lymphoma, as well as patients for whom a non-tumor tissue sample is available to serve as a technical reference.

Clinical, biological, therapeutic, and outcome data will be collected from medical records, and residual tissue samples originally obtained for routine clinical care will be processed according to standardized pre-analytical procedures and stored for future analysis.

The program comprises three complementary analytical sub-studies:

(i) a longitudinal, paired study comparing samples from the same patient at both the indolent and transformed stages, with the aim of characterizing the mechanisms of transformation; (ii) an investigation into the association between biological characteristics and therapeutic response within various groups of transformed B-cell lymphomas, with an exploration of whether these associations can be extrapolated to de novo diffuse large B-cell lymphoma (the most common lymphoma subtype, 15% of which exhibit therapeutic resistance); (iii) a prognostic study using samples obtained at the indolent stage to identify biological characteristics associated with the subsequent risk of transformation.

Analyses will be conducted separately for each lymphoma subtype, with Richter transformation and transformed follicular lymphoma serving as the primary models, while rarer forms will be the subject of exploratory analyses. Initial discovery-phase analyses will primarily relie on available retrospective samples. The identified biological findings and signatures will subsequently be evaluated within the prospective collection, following a pre-specified validation strategy. Longitudinal follow-up, planned for a maximum duration of ten years, will serve to document disease transformation, treatments received, therapeutic response, progression, and survival. Prospective samples will undergo standardized processing in a fresh state-including, wherever possible, the preparation of viable cell suspensions-to facilitate multi-omic, single-cell, spatial, and functional analyses, as well as the development of patient-derived models.

연구 유형

관찰

등록 (추정된)

710

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Nancy, 프랑스, 54000
        • University Hospital of Nancy
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The objective is to obtain a cohort of approximately 20 to 60 analyzable cases for each subtype of transformed B-cell lymphoma, enabling the exploration of molecular alterations associated with transformation, the study of mechanisms of therapeutic resistance, and the identification of biological signatures with theranostic relevance.

For technical and methodological reasons, a control group consisting of 20 non-tumor lymph node samples will be included in this study.

Recruitment objectives:

Recruitment target for the study group: 210 patients with transformed B-cell lymphoma

Recruitment targets for the 3 control subgroups:

  • 210 patients for the group with untransformed indolent B-cell lymphoma
  • 270 patients for the group with de novo diffuse large B-cell lymphoma
  • 20 patients for the control group

설명

Case groups: transformed B-cell lymphomas

Inclusion Criteria:

Patients who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

-with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

Patients in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup (including a tumor biopsy with histopathological analysis) is underway:

Richter transformation (RT) Transformed follicular lymphoma (tFL) Transformed marginal zone lymphoma (tMZL) Transformed lymphoplasmacytic lymphoma (tLPL) Blastoid mantle cell lymphoma

  • Cases subsequently confirmed as one of the following histological variants: DLBCL (Diffuse Large B-Cell Lymphoma), Hodgkin lymphoma, or blastoid variant
  • Cases for which biological samples potentially containing tumor cells are available and confirmed to contain a significant proportion of tumor cells (> 30%)
  • Patients for whom at least one of the following types of samples is available:

Circulating blood cells, plasma, serum, any sample of cerebrospinal fluid, pleural fluid, or peritoneal fluid, biopsies performed for the diagnosis and follow-up of the lymphoma, cells extracted from these biopsies

Exclusion Criteria:

  • Samples that do not meet the required diagnostic criteria
  • Samples that do not meet the quality criteria necessary for analysis
  • Samples that lack sufficient tumor content/representativeness for the requirements and analytical standards involved

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Case group : Transformed B-cell lymphoma

Patients :

- who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

Patients with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma:

CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

  • in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway: RT: Richter transformation tFL: transformed follicular Lymphoma tMZL: transformed marginal zone lymphoma tLPL: transformed lymphoplasmacytic lymphoma BL-MCL: blastoid mantle cell lymphoma
  • cases subsequently confirmed as one of the following histological variants: Diffuse large B-cell lymphoma, Hodgkin lymphoma, or a blastoid variant

Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

De novo aggressive lymphoma group (primarily de novo DLBCL)

Patients:

- who benefited from medical care at the Nancy University Hospital or the Metz-Thionville Regional Hospital.

Patients in whom a de novo aggressive B-cell lymphoma (DLBCL, Hodgkin lymphoma, or a blastoid variant) is suspected, and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway

  • with no prior history or concurrent diagnosis of a small B-cell lymphoma
  • for whom biological samples are available and confirmed to contain an adequate proportion of tumor cells (> 30%) These samples will be collected either as part of the diagnostic workupor during the course of follow-up

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

Indolent/small-cell non-transformed B-cell lymphomas group

Patients :

  • who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital
  • presenting with an indolent B-cell lymphoma, still untransformed at the corresponding index date, with a documented follow-up duration at least equal to the time interval between the diagnosis of the indolent lymphoma and the transformation observed in the transformed cases
  • for whom biological samples potentially containing tumor cells are available and contain an adequate proportion of tumor cells (> 30%) These samples will be collected either during the diagnostic work-up or during the course of follow-up

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Non-tumor patient" control group / lymph node tissue and blood free of tumor cells

Patients:

  • who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital
  • for whom one or more blood samples, serous fluid samples, and/or lymph node samples are available (either collected for suspected lymphoma or exploratory purposes, such as sentinel lymph node in solid-tumor oncology)
  • for whom the hypothesis of lymphoma or metastasis of solid cancer has been ruled out based on anatomopathological analysis (non-tumor samples)

Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of *de novo* DLBCLs
기간: 10 years

Outcome measure 1 : correlation between gene expression profiles at agressive stage, and response to treatment.

Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between protein expression profiles at agressive stage, and response to treatment.

Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : correlation between tumor microenvironment, and response to treatment.

Measurement : microenvironment profiling by flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-cells, CD8+ T-cells, macrophages) Treatment responses : good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease).

Signatures will be defined in a discovery cohort and subsequently confirmed in an independent cohort.

10 years

2차 결과 측정

결과 측정
측정값 설명
기간
Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
기간: 10 years

The analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma.

Outcome measure 1 : correlation between gene expression profiles at indolent stage, and the occurence of agressive transformation.

Measurement : whole transcriptome profiling Measurement tool : RNA-sequencing Unit of measure : transcripts rates

Outcome measure 2 : correlation between DNA methylation profiles at indolent stage, and the occurence of agressive transformation.

Measurement : whole methylome profiling Measurement tool : long read whole genome sequencing Unit of measure : methylation rates for 28 billion sites

Outcome measure 3 : correlation between proteomic profiles at indolent stage, and the occurence of agressive transformation.

Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : absolute numbers for each protein

10 years
Develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
기간: 10 years

Outcome measure 1 : gene expression profiles concordance between patient-derived experimental models and the original tumors.

Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : rate of transcripts

Outcome measure 2 : protein expression profiles concordance between patient-derived experimental models and the original tumors.

Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein

Outcome measure 3 : tumor microenvironment profiles concordance between patient-derived experimental models and the original tumors.

Measurement : microenvironment profiling by flow cytometry or immunohistochemistry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

10 years
To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
기간: 10 years

Outcome measure 1 : modification of gene expressions in malignant cells between the indolent stage, and the agressive transformation.

Measurement : gene expression Measurement tool : whole transcriptome sequencing (RNA-seq) Unit of measure : transcripts rates

Outcome measure 2 : modification of protein expressions in malignant cells between the indolent stage, and the agressive transformation.

Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein

Outcome measure 3 : modification of tumor microenvironment between the indolent stage, and the agressive transformation.

Measurement : microenvironment profiling Measurement tool : flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

10 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2036년 12월 1일

연구 완료 (추정된)

2036년 12월 1일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 13일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2024PI145

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Anonymized samples and clinical data will be shared with companion research teams.

Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

IPD 공유 기간

Start date : inclusion date end date : end of the study (decembre 2036)

IPD 공유 액세스 기준

Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

Data will be transfered with secured transfer protocols.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .